Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04933552 · ClinicalTrials.gov registry record
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
A clinical trial of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 867
- Enrollment target
- 1
- Study location
NCT04933552 is a study of Multiple Sclerosis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 867 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04933552, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 867 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
Conditions Studied
Interventions
- OTHER Siponimod
Study Locations (1)
California
- Novartis Investigative Site - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 867 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2032-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04933552
The ClinicalTrials.gov registry entry for NCT04933552 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 867 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Siponimod is the first listed.
NCT04933552 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04933552 about?
NCT04933552 is a clinical study titled "Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent". This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
What is the current status of trial NCT04933552?
This trial is currently recruiting. The enrollment target is 867 participants. The study started on 2021-12-15. Estimated completion is 2032-05-31.
What conditions does trial NCT04933552 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT04933552?
The interventions under investigation include: Siponimod (OTHER).
Who is sponsoring clinical trial NCT04933552?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04933552 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.